Erlotinib accumulation in brain metastases from non-small cell lung cancer: Avisualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1287-1289

  Weber, Britta ^a   Winterdahl, Michael ^a   Memon, Ashfaque ^a   Sorensen, Boe S ^a   Keiding, Susanne ^a   Sorensen, Leif ^a   Nexo, Ebba ^a   Meldgaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain metastases; EGFR mutation; Erlotinib; NSCLC; PET

Indexed keywords

CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER REGRESSION; CARCINOMATOUS MENINGITIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG UPTAKE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NAUSEA; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; PRIORITY JOURNAL; PUSTULE; TUMOR BIOPSY; VISUAL IMPAIRMENT;

ADULT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959914514     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318219ab87     Document Type: Article

References (15)

1. Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007;19:2013-2023. (Pubitemid 47353811)
2. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-414.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
5. Yoshida K, Yatabe Y, Park J, et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol 2010;136:527-535.
6. Sulim S, Hoyer M. [Meningeal carcinomatosis]. Ugeskr Laeger 2005; 167:3481-3484.
7. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003;21: 1-23, vii. (Pubitemid 36169343)
8. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998;82:1756-1763. (Pubitemid 28208928)
9. Gounant V, Wislez M, Poulot V, et al. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer 2007;58:425-428. (Pubitemid 350064403)
10. Poon AN, Ho SS, Yeo W, et al. Brain metastasis responding to gefitinib alone. Oncology 2004;67:174-178. (Pubitemid 39482687)
11. Popat S, Hughes S, Papadopoulos P, et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 2007;56:135-137. (Pubitemid 46356639)
12. Memon AA, Jakobsen S, gnaes-Hansen F, et al. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts. Cancer Res 2009;69:873-878.
13. Mulloy R, Ferrand A, Kim Y, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-2330. (Pubitemid 46424253)
14. Lind JS, Postmus PE, Heideman DA, et al. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. J Thorac Oncol 2009;4:1585-1586.
15. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009;65:351-354.